It is increasingly recognized that galactose-deficient IgA in the glomerulus activates the alternative complement system and drives IgA nephropathy, including in the tubules and interstitium, leading ...

Fossil fuels will dominate India's energy for 10-15 years, says BPCL's Anurag Saraogi. He states that biofuels will complement, not replace, conventional sources as India makes strides in ethanol ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, across generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN) and ...

Their structural adjustment programmes routinely mandate austerity cuts, mass privatisation and Western-style institutional ...

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28 ...

Both the Princess of Wales and King Charles have been through cancer diagnoses, with the in-laws able to support one another ...

IIT Kanpur scientists have unlocked the mystery behind the C5aR2 immune receptor's unique function. Using advanced cryo-EM, ...

Atlas Copco rental models are offering flexible access to electric, oil-free compressed air as rising fuel costs and stricter ...

Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, June 18, 2026, beginning at ...

The COMMUTE-p and COMMUTE-a phase 3 trials assessed subcutaneous crovalimab, a C5 inhibitor with longer half-life, in children and adults with aHUS.